Egy új típusú antiemetikum, az 5-HT3 receptor antagonista ondansetron alkalmazása gyermekonkológiában.

Translated title of the contribution: Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology

C. Csáki, T. Ferencz, R. Koós, D. Schuler, J. Borsi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The effectiveness of the new antiemetic drug, the 5-hydroxytryptamin (5-HT) receptor antagonist ondansetron was evaluated in paediatric cancer patients. 5-HT3 antagonists represent a new class of drugs effective in the control of chemo- and radiotherapy-induced emesis. Based on their selectivity 5-HT3 antagonist are free from extrapyramidal side effects, a major problem in children in the case of currently used dopamine receptor antagonists (e.g. metoclopramide). In this study ondansetron was tested as antiemetic in 33 children with malignant disease (132 chemotherapy cycles) treated with: 1. high-dose cisplatin (120 mg/m2), 2. intermediate-dose cisplatin (60 mg/m2) and 3. no cisplatin-containing, combined high-dose chemotherapy. Ondansetron was found to be safe and effective in the control of acute and delayed emesis in all treatment groups. Its effectiveness was superior to the currently used antiemetic drugs in the period of acute emesis.

Original languageHungarian
Pages (from-to)1363-1367
Number of pages5
JournalOrvosi Hetilap
Volume134
Issue number25
Publication statusPublished - Jun 20 1993

Fingerprint

Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Ondansetron
Antiemetics
Cisplatin
Vomiting
Pediatrics
Drug Therapy
Metoclopramide
Dopamine Antagonists
Radiotherapy
Pharmaceutical Preparations
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Egy új típusú antiemetikum, az 5-HT3 receptor antagonista ondansetron alkalmazása gyermekonkológiában. / Csáki, C.; Ferencz, T.; Koós, R.; Schuler, D.; Borsi, J.

In: Orvosi Hetilap, Vol. 134, No. 25, 20.06.1993, p. 1363-1367.

Research output: Contribution to journalArticle

Csáki, C. ; Ferencz, T. ; Koós, R. ; Schuler, D. ; Borsi, J. / Egy új típusú antiemetikum, az 5-HT3 receptor antagonista ondansetron alkalmazása gyermekonkológiában. In: Orvosi Hetilap. 1993 ; Vol. 134, No. 25. pp. 1363-1367.
@article{a389610c695b4b19bebc03de274bf251,
title = "Egy {\'u}j t{\'i}pus{\'u} antiemetikum, az 5-HT3 receptor antagonista ondansetron alkalmaz{\'a}sa gyermekonkol{\'o}gi{\'a}ban.",
abstract = "The effectiveness of the new antiemetic drug, the 5-hydroxytryptamin (5-HT) receptor antagonist ondansetron was evaluated in paediatric cancer patients. 5-HT3 antagonists represent a new class of drugs effective in the control of chemo- and radiotherapy-induced emesis. Based on their selectivity 5-HT3 antagonist are free from extrapyramidal side effects, a major problem in children in the case of currently used dopamine receptor antagonists (e.g. metoclopramide). In this study ondansetron was tested as antiemetic in 33 children with malignant disease (132 chemotherapy cycles) treated with: 1. high-dose cisplatin (120 mg/m2), 2. intermediate-dose cisplatin (60 mg/m2) and 3. no cisplatin-containing, combined high-dose chemotherapy. Ondansetron was found to be safe and effective in the control of acute and delayed emesis in all treatment groups. Its effectiveness was superior to the currently used antiemetic drugs in the period of acute emesis.",
author = "C. Cs{\'a}ki and T. Ferencz and R. Ko{\'o}s and D. Schuler and J. Borsi",
year = "1993",
month = "6",
day = "20",
language = "Hungarian",
volume = "134",
pages = "1363--1367",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "25",

}

TY - JOUR

T1 - Egy új típusú antiemetikum, az 5-HT3 receptor antagonista ondansetron alkalmazása gyermekonkológiában.

AU - Csáki, C.

AU - Ferencz, T.

AU - Koós, R.

AU - Schuler, D.

AU - Borsi, J.

PY - 1993/6/20

Y1 - 1993/6/20

N2 - The effectiveness of the new antiemetic drug, the 5-hydroxytryptamin (5-HT) receptor antagonist ondansetron was evaluated in paediatric cancer patients. 5-HT3 antagonists represent a new class of drugs effective in the control of chemo- and radiotherapy-induced emesis. Based on their selectivity 5-HT3 antagonist are free from extrapyramidal side effects, a major problem in children in the case of currently used dopamine receptor antagonists (e.g. metoclopramide). In this study ondansetron was tested as antiemetic in 33 children with malignant disease (132 chemotherapy cycles) treated with: 1. high-dose cisplatin (120 mg/m2), 2. intermediate-dose cisplatin (60 mg/m2) and 3. no cisplatin-containing, combined high-dose chemotherapy. Ondansetron was found to be safe and effective in the control of acute and delayed emesis in all treatment groups. Its effectiveness was superior to the currently used antiemetic drugs in the period of acute emesis.

AB - The effectiveness of the new antiemetic drug, the 5-hydroxytryptamin (5-HT) receptor antagonist ondansetron was evaluated in paediatric cancer patients. 5-HT3 antagonists represent a new class of drugs effective in the control of chemo- and radiotherapy-induced emesis. Based on their selectivity 5-HT3 antagonist are free from extrapyramidal side effects, a major problem in children in the case of currently used dopamine receptor antagonists (e.g. metoclopramide). In this study ondansetron was tested as antiemetic in 33 children with malignant disease (132 chemotherapy cycles) treated with: 1. high-dose cisplatin (120 mg/m2), 2. intermediate-dose cisplatin (60 mg/m2) and 3. no cisplatin-containing, combined high-dose chemotherapy. Ondansetron was found to be safe and effective in the control of acute and delayed emesis in all treatment groups. Its effectiveness was superior to the currently used antiemetic drugs in the period of acute emesis.

UR - http://www.scopus.com/inward/record.url?scp=0027921060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027921060&partnerID=8YFLogxK

M3 - Article

VL - 134

SP - 1363

EP - 1367

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 25

ER -